Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

<h4>Background and aims</h4>Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis. We hypothesized that inhibition of VEGFR and FGFR b...

Full description

Saved in:
Bibliographic Details
Main Authors: Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0092273&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0092273&type=printable

Similar Items